EUVIMEDEUVIMED entdecken
Crossref

The efficacy and safety of therapeutic thrombocytapheresis in patients with extreme thrombocytosis

Serhat Çelik iD, Zeynep Tuğba Güven iD, Muzaffer Keklik iD, Ali Ünal iD, Leylagül Kaynar iD

Transfusion Medicine · 2025

DOI: 10.1111/tme.13150 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion Medicine, 2025. Verfasst von Serhat Çelik und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Ankara Yenimahalle Training and Research Hospital, TC Health Ministry, Ankara, Turkey. Hauptthemen laut MEDLINE: Thrombocytosis, Plateletpheresis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Therapeutic thrombocytapheresis (TTA) is used to promptly reduce platelet count to prevent thrombohemorrhagic complications that may develop in extreme thrombocytosis. In this study, the efficacy and safety of TTA were investigated in our patients who underwent TTA for extreme thrombocytosis for more than 20 years. Materials and Methods Forty‐four patients who underwent TTA due to extreme thrombocytosis between January 2000 and December 2021 in Erciyes University, Faculty of Medicine Therapeutic Apheresis Unit were analysed retrospectively. Extreme thrombocytosis was defined as a platelet count >1000 × 10 9 /L.

Results

The median percentage of platelet reduction was 62.2% (28.6%–90.1%). TTA was administered with Spectra Optia in 45.5% ( n = 20) and Fresenius in 54.5% ( n = 24) of the patients. No statistically significant difference was observed between age, gender, diagnoses, and devices used regarding TTA efficiency. The percentage of platelet reduction was higher in those who had a platelet precount above 1500 × 10 9 /L than those who did not (64.5% ± 9.9% vs. 57.3% ± 12.9%, p = 0.045). No major complications were observed. Mild side effects were observed in five (11.4%) patients.

Conclusion

TTA provided prompt, effective, and safe reduction of platelet count in the treatment of extreme thrombocytosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombocytosisPlateletpheresisHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAdultPlatelet CountAged, 80 and over

Stichwörter der Autor:innen

apheresisextreme thrombocytosisplateletthrombocytapheresis

Autor:innen und Institutionen

  • Department of Hematology, Ankara Yenimahalle Training and Research Hospital, TC Health Ministry, Ankara, Turkey.
  • Department of Hematology, Adana City Training and Research Hospital, TC Health Ministry, Adana, Turkey.
  • Department of Hematology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.
  • Department of Hematology, International School of Medicine, İstanbul Medipol University, İstanbul, Turkey.

ORCID-Profile: Serhat Çelik, Zeynep Tuğba Güven, Muzaffer Keklik, Ali Ünal, Leylagül Kaynar

Zitieren

APA

Çelik, S., Güven, Z. T., Keklik, M., Ünal, A., & Kaynar, L. (2025). The efficacy and safety of therapeutic thrombocytapheresis in patients with extreme thrombocytosis. Transfusion Medicine. https://doi.org/10.1111/tme.13150

Vancouver

Çelik S, Güven ZT, Keklik M, Ünal A, Kaynar L. The efficacy and safety of therapeutic thrombocytapheresis in patients with extreme thrombocytosis. Transfusion Medicine. 2025. doi:10.1111/tme.13150

BibTeX
@article{elik2025,
  author = {Çelik, Serhat and Güven, Zeynep Tuğba and Keklik, Muzaffer and Ünal, Ali and Kaynar, Leylagül},
  title = {The efficacy and safety of therapeutic thrombocytapheresis in patients with extreme thrombocytosis},
  journal = {Transfusion Medicine},
  year = {2025},
  doi = {10.1111/tme.13150}
}
Kostenlos starten →